Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

581
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
581
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

848
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
848
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.1K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

748
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
748
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

779
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
779
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

3.0K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Image Inpainting-Based Point Cloud Restoration for Enhancing Tactical Classification of Unmanned Surface Vehicles.

Sensors (Basel, Switzerland)·2026
Same author

Clinical features and outcome predictors in benign paroxysmal positional vertigo and its variant: Perspective in a primary care neurology clinic.

Journal of vestibular research : equilibrium & orientation·2025
Same author

Clinical features of secondary BPPV: A nation-wide multicenter study.

Journal of vestibular research : equilibrium & orientation·2025
Same author

Erratum: Effects of the Loss of Mismatch Repair Genes on Single-Strand Annealing Between Divergent Sequences in Saccharomyces cerevisiae.

Journal of microbiology (Seoul, Korea)·2024
Same author

Erratum: Analyses of DNA Double-Strand Break Repair Pathways in Tandem Arrays of HXT Genes of Saccharomyces Cerevisiae.

Journal of microbiology (Seoul, Korea)·2024
Same author

Efficacy of vestibular rehabilitation and its facilitating and hindering factors from real-world clinical data.

Frontiers in neurology·2024

Related Experiment Video

Updated: Jan 5, 2026

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

990

Negative myoclonus associated with pregabalin.

Kwan-Do Park1, Min-Ku Kim1, Se-Jin Lee1

  • 1Department of Neurology, Yeungnam University College of Medicine, Daegu, Korea.

Yeungnam University Journal of Medicine
|October 18, 2019
PubMed
Summary
This summary is machine-generated.

Pregabalin can trigger negative myoclonus (NM), a type of involuntary movement, even in individuals without prior seizure history. Discontinuing the medication and using lorazepam led to symptom resolution in an elderly patient.

Keywords:
MyoclonusNegative myoclonusPregabalin

More Related Videos

Generation of Local CA1 γ Oscillations by Tetanic Stimulation
08:02

Generation of Local CA1 γ Oscillations by Tetanic Stimulation

Published on: August 14, 2015

9.4K
Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants
18:01

Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants

Published on: August 18, 2008

14.6K

Related Experiment Videos

Last Updated: Jan 5, 2026

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

990
Generation of Local CA1 γ Oscillations by Tetanic Stimulation
08:02

Generation of Local CA1 γ Oscillations by Tetanic Stimulation

Published on: August 14, 2015

9.4K
Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants
18:01

Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants

Published on: August 18, 2008

14.6K

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Negative myoclonus (NM) is characterized by sudden, brief interruptions in muscle contraction, presenting as jerky, shock-like involuntary movements.
  • Neuropathic pain management often involves medications like pregabalin.

Observation:

  • An 80-year-old male patient developed multifocal NM and confusion.
  • The onset of NM occurred two days after initiating pregabalin (150 mg/day) for neuropathic pain.

Findings:

  • Intravenous lorazepam administration and discontinuation of pregabalin resulted in complete resolution of NM.
  • The patient's mental status gradually improved following these interventions.

Implications:

  • This case suggests a potential causal link between pregabalin and negative myoclonus.
  • Healthcare providers should consider pregabalin as a potential cause of NM, particularly in patients without a history of seizures.
  • Awareness of this adverse effect is crucial for accurate diagnosis and management of involuntary movements in patients taking pregabalin.